---
figid: PMC6135718__nihms944158f5
figtitle: 'Lymphangiogenesis therapies: learning from current anti-angiogenesis therapies
  - A review'
organisms:
- NA
pmcid: PMC6135718
filename: nihms944158f5.jpg
figlink: /pmc/articles/PMC6135718/figure/F5/
number: F5
caption: Axitinib, Bevacizumab, Cabozantinib, Nintedanib, Pazopanib, Pegaptanib, Ramuricumab,
  Ranibizumab, Regorafenib, Sorafenib, Sunitinib, and Vandetanib are approved anti-angiogenic
  therapies that target VEGF-mediated angiogenesis. Inhibition of a VEGF ligand, a
  VEGFR binding site, or VEGFR tyrosine kinase activity leads to a reduction in angiogenesis.
  This strategy can potentially be translated for lymphangiogenesis-targeted drug
  design. Development of anti-lymphangiogenic therapies may follow the design of anti-angiogenic
  therapies by interrupting the lymphangiogenic factor VEGF-C, its receptors VEGFR2
  and VEGFR3, or the tyrosine kinase activity of VEGFR2 and VEGFR3. HA, hemangiogenic;
  LA, lymphangiogenic.
papertitle: 'Potential lymphangiogenesis therapies: learning from current anti-angiogenesis
  therapies - A review.'
reftext: Michael Yamakawa, et al. Med Res Rev. 2018 Sep;38(6):1769-1798.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9464964
figid_alias: PMC6135718__F5
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC6135718__F5
ndex: 157f87af-dece-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6135718__nihms944158f5.html
  '@type': Dataset
  description: Axitinib, Bevacizumab, Cabozantinib, Nintedanib, Pazopanib, Pegaptanib,
    Ramuricumab, Ranibizumab, Regorafenib, Sorafenib, Sunitinib, and Vandetanib are
    approved anti-angiogenic therapies that target VEGF-mediated angiogenesis. Inhibition
    of a VEGF ligand, a VEGFR binding site, or VEGFR tyrosine kinase activity leads
    to a reduction in angiogenesis. This strategy can potentially be translated for
    lymphangiogenesis-targeted drug design. Development of anti-lymphangiogenic therapies
    may follow the design of anti-angiogenic therapies by interrupting the lymphangiogenic
    factor VEGF-C, its receptors VEGFR2 and VEGFR3, or the tyrosine kinase activity
    of VEGFR2 and VEGFR3. HA, hemangiogenic; LA, lymphangiogenic.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ab
  - Appl
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - ha
  - La
  - APP
  - SUCLA2
  - VEGFC
  - TRAP
  - ACP5
  - CD40LG
  - TRAF2
  - TRRAP
  - TDRD7
  - SCYL1
  - VEGFA
  - VEGFB
  - VEGFD
  - PGF
  - KDR
  - FLT1
  - FLT4
  - Pegaptanib
  - H
  - Tyrosine
  - Axitinib
  - Cabozantinib
  - Nintedanib
  - Pazopanib
  - Regorafenib
  - Sorafenib
  - Sunitinib
  - Vandetanib
---
